Amelia Insa
Medical Oncology Service. Hospital Clínico Universitario - Valencia (Spain)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amelia Insa as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:37 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT00503971 · Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.Spanish Lung Cancer Group · terminated · Non-small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:37 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- 4,648 citationsRCR 126.2
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.Lancet Oncol · 2020767 citationsRCR 29.7
- Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.N Engl J Med · 2023478 citationsRCR 35.9
- Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).J Clin Oncol · 2022332 citationsRCR 20.8
- Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.JAMA Oncol · 2015216 citationsRCR 6.4
- Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.J Thorac Oncol · 2019108 citationsRCR 3.6
- Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.Lancet Oncol · 202499 citationsRCR 8.8
- 83 citationsRCR 2.2
- 77 citationsRCR 1.9
- Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.J Immunother Cancer · 202261 citationsRCR 3.5